Medicus Pharma (MDCX) Operating Expenses (2024 - 2026)
Medicus Pharma's (MDCX) quarterly Operating Expenses came in at $7.8 million in Q4 2025, up 117.28% YoY from $3.6 million in Q4 2024, and up 51937233.33% on a QoQ basis from $15.0 in Q3 2025.
Medicus Pharma (MDCX) Operating Expenses (2024 - 2026) Analysis & Trends
Medicus Pharma (MDCX) has 2 years of Operating Expenses data on file, last reported at $7.8 million in Q4 2025.
- Quarterly Operating Expenses rose 117.28% year-over-year to $7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18.9 million (up 69.33% YoY) and the FY2025 annual result came in at $34.4 million, up 207.3% from the prior year.
- Operating Expenses advanced to $7.8 million in Q4 2025, from $15.0 in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $7.8 million in Q4 2025 to a low of $15.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.18 Bn | 632.42 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 470.31 Bn | 463.74 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 377.76 Bn | 370.62 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 303.30 Bn | 295.61 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 257.84 Bn | 252.94 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 236.85 Bn | 222.86 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 182.10 Bn | 178.92 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 159.40 Bn | 147.70 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 106.36 Bn | 102.19 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Medicus Pharma | 14.61 Mn | -567,976.50 | - | 11.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.48 Mn |
| Dec 31, 2025 | 7.79 Mn |
| Sep 30, 2025 | 15.00 |
| Jun 30, 2025 | 6.02 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Dec 31, 2024 | 3.59 Mn |
| Sep 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 3.55 Mn |
| Mar 31, 2024 | 1.71 Mn |